Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Devel
Go back to Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Devel| (NASDAQ: AUPH) | Delayed: 17.84 +0.31 (1.77%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $17.53 | 52 Week High | $5.69 | |||
| Open | $17.39 | 52 Week Low | $1.42 | |||
| Day High | $17.97 | P/E | N/A | |||
| Day Low | $17.07 | EPS | $0.00 | |||
| Volume | 1,679,175 | |||||
